Akebia Therapeutics, Inc.
AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adulā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.59
Price-1.24%
-$0.02
1Y
Price
Market Cap
$421.932m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+10.6%
EBITDA Margin+0.9%
Net Profit Margin+47.7%
Free Cash Flow Margin+10.6%
EBITDA Margin+0.9%
Net Profit Margin+47.7%
Free Cash Flow MarginRevenue
$225.071m
+40.5%
1y CAGR-3.5%
3y CAGR+6.9%
5y CAGREarnings
-$15.905m
+77.1%
1y CAGR+29.4%
3y CAGR+38.7%
5y CAGREPS
-$0.07
+78.8%
1y CAGR+37.6%
3y CAGR+43.4%
5y CAGRBook Value
$41.592m
$364.152m
Assets$322.560m
Liabilities$52.577m
DebtDebt to Assets
14.4%
2.5x
Debt to EBITDAFree Cash Flow
$32.174m
+179.1%
1y CAGR+57.7%
3y CAGR+61.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company